Csl vifor and travere therapeutics announce swissmedic approval of filspari® (sparsentan) for the treatment of iga nephropathy

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-iii protect trial st. gallen, switzerland and san diego, oct. 17, 2024 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) today announced that swissmedic has granted temporary marketing authorization for filspari for the treatment of adults with primary iga nephropathy (igan) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
TVTX Ratings Summary
TVTX Quant Ranking